Current Report Filing (8-k)
October 16 2017 - 4:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 16, 2017
OVID
THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-38085
|
|
46-5270895
|
(state or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
1460 Broadway, Suite 15044
New York, New York
|
|
|
|
10036
|
(Address of principal executive offices)
|
|
|
|
(Zip Code)
|
Registrants telephone number, including area code: (646)
661-7661
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b2 of the Securities Exchange Act of 1934 (§ 240.12b2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 8.01. Other Events.
On October 16, 2017, Ovid Therapeutics Inc. (the Company) issued a press release announcing initial data from an analysis of
the Companys ongoing
pre-clinical
study of OV101 in patients with Fragile X syndrome, which data were presented at the 18th International Fragile X and Related Neurodevelopmental Disorders Workshop.
A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form
8-K
and is
incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
OVID THERAPEUTICS INC.
|
|
|
By:
|
|
/s/ Ana C. Ward
|
|
|
Ana C. Ward
Senior Vice President &
General Counsel
|
Dated: October 16, 2017
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Apr 2023 to Apr 2024